Biotechnology And Bioengineering Are Coming To The Forefront
Biotechnology and bioengineering are sciences which may have the opportunity to alter the manner in which basic industries such as agriculture are carried out arround the world, and to achieve this in the most dramatic way. It is possible to create new strains of crops which could have far higher average yields, as a result of a higher resistance against disease and even against naturally occurring weather conditions. The science of biotechnology has reached the stage where it's turning theories into realities, which can result in major benefits for the entire population of the planet.
These industries have inevitably taken time for them to make it to the point they're at today. There is a natural progression which can be observed in the growth of industries and new technologies throughout history. A new development will start off extremely slowly, with only a handful of visionaries able to carry out experiments which will take the science forward. When the first successful advances are made, momentum begins to pick up. It is at the point when the science can be applied commercially that it really begins to take off, as financial backers will now see the chance of a significant profit over time.
This stage has been passed through the use of biotechnology in agriculture. There are crops which have been produced to allow food to remain fresher for a longer period of time, and also crops which are resistant against disease. This greatly affects the consumption of staple food items such as rice and bread. In Africa, for instance, there is regular wastage of the rice crop and a significant danger of famine which biotechnology can eliminate. In the West, large quantities of bread are thrown away when they become inedible, and the technology for growing longer lasting bread is already here.
The application of biotechnology and bioengineering in pharmaceutical development isn't very well advanced, however the possibility for future profit is assured. Many drugs are needed in huge quantities to satisfy the demands of people who need to use them regularly, and drug production can be increased through biotechnology. A classic case is insulin, which can be produced from a variety of sources and which is easily absorbed by the body in any case. It is possible to produce far higher quantities of insulin at a cheaper price using biotechnology, and the benefit to diabetics worldwide will be enormous.
It's to generally be admitted there presently exists controversial aspects to bioengineering especially, and therefore many intelligent individuals are concerned about the potential misuse of the technology. We have now passed the point where it is possible to clone an animal from a pre-existing specimen, and this inevitably brings us to the question of whether human beings may one day be cloned. There are obviously horrifying implications to this possibility, although the ability to clone replacement limbs or organs for a human being could be a highly positive step and could eliminate unnecessary transplants.
No matter what the future of biotechnology and bioengineering might be, you can be certain that they'll play a substantial role in the economic development of the West for quite some time to come. There are many difficult problems within out society which can potentially be solved by the use of these technologies, and it can happen in a way which will have knock on benefits throughout the entire world. If you are looking for sector in which to invest your money with an excellent chance of high reward, then this is a sector to look at closely. As long as you cover your risk with investments which have greater safety, you can benefit from investing in biotechnology and bioengineering.Richard Tipsword
|Which biopharm firms got a head start by winning JumpStart? - Philadelphia Business Journal (blog)|
Oncolytics Biotech Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC
Oncolytics Biotech Inc. Announces Amendment to Common Share Purchase Agreement with Lincoln Park Capital Fund, LLC..
Biotech bucks macro uncertainties - strong quarterly results for BB Biotech
Interim Report of BB Biotech AG as of September 30, 2014 BB Biotech advances 18.2% (in CHF) in the third quarter 2014 The biotechnology industry continues to advance despite the unsteady trends on global ...
Morphosys raises forecasts on Janssen Biotech milestone payment
German biotech company Morphosys raised its earnings forecast for 2014, citing a milestone payment from Janssen Biotech as well as a partial shift of development costs to 2015. Morphosys said in a statement on Thursday that its partner Janssen started a late-stage clinical trial of antibody guselkumab to treat moderate to severe psoriasis, triggering a payment to the German group...
CSUN awarded $22 million to enhance diversity in biomedical workforce - MyNewsLA.com
From Rock-'n'-Roller to Biomedical Scientist - News from Rutgers